Skip to main content
. 2012 Apr 30;2012:384936. doi: 10.1100/2012/384936

Figure 1.

Figure 1

Treatments to obtain PCMOs and MOMPs influence proliferation and expression of monocytes. (a) Human mononuclear cells (N = 4, n = 3) were cultivated without specific treatment (Mo), treated for 6 days to obtain MOMPs (M) or PCMOs (P). Viability was measured by Alamar blue assay on day 6. P shows a significantly higher viability than Mo (***P < 0.001). (b) Relative expression levels of CD34 measured by RT-PCR normalized to GAPDH and subsequently to expression of CD34 in nonadherent bone marrow cells (naBMCs) as internal control (N = 3, n = 3). Mo and M show a significantly higher expression of CD34 on day 6 than Mo on day 1 (**P < 0.01; ***P < 0.001). After osteogenic differentiation, CD34 levels in Mo decreased significantly in comparison to Mo on day 6 (°°P < 0.05). (c) Relative expression levels of collagen type 1 measured by RT-PCR normalized to GAPDH and subsequently to expression of collagen type 1 in primary osteoblasts (O) as internal control (N = 3, n = 3). Mo, M and P show expression of low levels of collagen type 1 on all days (***P < 0.001). Monocytes (Mo) day 1: freshly isolated monocytes; Mo, MOMP (M), and PCMO (P) day 6: cells after treatment; Mo, M, P day 20: cells after differentiation with vitamin D containing medium.